{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:55:03Z","timestamp":1792169703457,"version":"4.4.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/ibd\/izag216","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:52:46Z","timestamp":1790855566000},"source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 receptor agonists and symptomatic remission in ulcerative colitis: A credible signal that welcomes prospective study"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2734-4460","authenticated-orcid":false,"given":"Budoor","family":"Alqinai","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, Department of Medicine, West Virginia University , Morgantown, WV,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapna","family":"Gayam","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, West Virginia University , Morgantown, WV,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hadam-Veverka","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, West Virginia University , Morgantown, WV,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"2026101612363437200_izag216-B1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izag167","article-title":"GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study","author":"Alqinai","year":"2026","journal-title":"Inflamm Bowel Dis"},{"key":"2026101612363437200_izag216-B2","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"2026101612363437200_izag216-B3","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1136\/gutjnl-2021-326390","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","volume":"71","author":"Burr","year":"2022","journal-title":"Gut"},{"key":"2026101612363437200_izag216-B4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/ecco-jcc\/jjw004","article-title":"Systematic review and meta-analysis: placebo rates in induction and maintenance trials of ulcerative colitis","volume":"10","author":"Jairath","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2026101612363437200_izag216-B5","doi-asserted-by":"publisher","first-page":"jjaf191","DOI":"10.1093\/ecco-jcc\/jjaf191","article-title":"Placebo rates in randomized clinical trials of ulcerative colitis: an individual patient data meta-analysis","volume":"19","author":"Solitano","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026101612363437200_izag216-B6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1365-2982.2007.01079.x","article-title":"GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome","volume":"20","author":"Hellstr\u00f6m","year":"2008","journal-title":"Neurogastroenterol Motil"},{"key":"2026101612363437200_izag216-B7","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/j.cgh.2015.05.038","article-title":"Level of fecal calprotectin correlates with endoscopic and histologic inflammation and identifies patients with mucosal healing in ulcerative colitis","volume":"13","author":"Theede","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026101612363437200_izag216-B8","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1093\/ibd\/izae005","article-title":"Diagnostic performance of a fecal calprotectin assay as a biomarker for Mayo endoscopic subscore in ulcerative colitis: result from a tertiary referral center","volume":"30","author":"Suttichaimongkol","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026101612363437200_izag216-B9","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.2337\/db14-1577","article-title":"GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R","volume":"64","author":"Yusta","year":"2015","journal-title":"Diabetes"},{"key":"2026101612363437200_izag216-B10","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1097\/MIB.0000000000000847","article-title":"GLP-1 induces barrier protective expression in Brunner\u2019s glands and regulates colonic inflammation","volume":"22","author":"Bang-Berthelsen","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026101612363437200_izag216-B11","doi-asserted-by":"publisher","first-page":"8044","DOI":"10.18632\/aging.204953","article-title":"The alleviating effect and mechanism of GLP-1 on ulcerative colitis","volume":"15","author":"Wang","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"2026101612363437200_izag216-B12","doi-asserted-by":"publisher","first-page":"100979","DOI":"10.1016\/j.eclinm.2021.100979","article-title":"GLP-1 based therapies and disease course of inflammatory bowel disease","volume":"37","author":"Villumsen","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2026101612363437200_izag216-B13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/apt.18138","article-title":"Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease","volume":"60","author":"Desai","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026101612363437200_izag216-B14","doi-asserted-by":"publisher","first-page":"jjaf181","DOI":"10.1093\/ecco-jcc\/jjaf181","article-title":"Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis","volume":"19","author":"Bayoumy","year":"2025","journal-title":"J Crohns Colitis"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag216\/72048723\/izag216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag216\/72048723\/izag216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:36:37Z","timestamp":1792168597000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article\/doi\/10.1093\/ibd\/izag216\/8931653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":14,"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag216","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"article-number":"izag216"}}